AMLXHealthcare · Drug Manufacturers - Specialty & GenericThe 12 Wall Street analysts covering Amylyx Pharmaceuticals, Inc. hold a median 12-month price target of $42 — +29.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 57 of 100 as at 19 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Amylyx Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Revisions (35): Analysts have, on balance, been cutting their forecasts.
Size (26): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AMLX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +29.6% from it.
Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Aug 2026 | Guggenheim | Maintains | Buy | $55 → $57 |
| 19 Aug 2026 | Baird | Maintains | Outperform | — |
| 19 Aug 2026 | Baird | Maintains | Outperform | $28 → $52 |
| 19 Aug 2026 | Guggenheim | Maintains | Buy | — |
| 19 Aug 2026 | Guggenheim | Maintains | Buy | $40 → $55 |
| 19 Aug 2026 | Mizuho | Maintains | Outperform | $30 → $42 |
| 19 Aug 2026 | Mizuho | Maintains | Outperform | — |
| 18 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $34 → $55 |
| 18 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Aug 2026 | Mizuho | Maintains | Outperform | — |
| 17 Aug 2026 | Mizuho | Maintains | Outperform | $24 → $30 |
| 3 Aug 2026 | Citigroup | Maintains | Buy | — |
| 3 Aug 2026 | Citigroup | Maintains | Buy | $20 → $26 |
| 20 July 2026 | Mizuho | Maintains | Outperform | — |
| 20 July 2026 | Mizuho | Maintains | Outperform | $21 → $24 |
| 25 June 2026 | Guggenheim | Maintains | Buy | $30 → $40 |
| 25 June 2026 | Guggenheim | Maintains | Buy | — |
| 28 Apr 2026 | Mizuho | Maintains | Outperform | — |
| 25 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Mar 2026 | Guggenheim | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AMLX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, Amylyx Pharmaceuticals, Inc. returned +144.6% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 69% of US stocks
Cheaper than 6% of US stocks
Cheaper than 89% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 17% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Amylyx Pharmaceuticals, Inc. has a market value of $3.6B and an enterprise value of $3.4B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$152.1M.
Diluted earnings per share, trailing twelve months: $−1.43.
Free cash flow in the twelve months to 30 June 2026: −$126.7M.
Trailing P/E: 2.5×; forward P/E: −28.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Amylyx Pharmaceuticals, Inc. employs 136 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Amylyx Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Amylyx Pharmaceuticals presented at the Morgan Stanley 24th Annual Global Healthcare Conference. A transcript of the presentation was made available on Seeking Alpha.
Why it matters — An AMLX watcher would care because a conference presentation offers an opportunity to hear the company's latest commentary in an investor forum.
Amylyx Pharmaceuticals announced it will present at the 24th Annual Morgan Stanley Global Healthcare Conference, as reported by Business Wire. The announcement concerns the company's upcoming participation at the investor conference.
Why it matters — Presenting at a major healthcare investor conference gives AMLX watchers a scheduled opportunity to hear updates from the company's leadership.
Amylyx Pharmaceuticals raised $500 million to strengthen its balance sheet, according to The Motley Fool. The company has a potential drug launch in 2027 that could serve as its next catalyst. The article discusses the stock's significant rise of 247%.
Why it matters — Amylyx watchers would care because the company has secured additional funding and has a potential 2027 drug launch that could be a meaningful catalyst.
A MarketWatch report identifies 20 stocks, described as poor bets, that are likely to lose ground even if the broader bull market continues. The excerpt notes these stocks may decline regardless of overall market conditions.
Why it matters — Amylyx watchers would care because the report's identification of stocks expected to lag in a rising market could bear on how AMLX is viewed relative to the broader market.
Amylyx Pharmaceuticals' stock rose nearly 79% this week after analysts raised their price targets on the company and it launched a new round of capital raising.
Why it matters — For an Amylyx watcher, the sharp stock surge and analyst price-target hikes signal renewed investor confidence, while the capital raise could fund future operations or pipeline development.
The 12 Wall Street analysts covering Amylyx Pharmaceuticals, Inc. have a median 12-month price target of $42, with estimates ranging from $20 to $57. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Amylyx Pharmaceuticals, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Amylyx Pharmaceuticals, Inc. 57 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Sept 2026, Amylyx Pharmaceuticals, Inc. ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +29.6% from the last close, and Ticker Nerd's factor model ranks Amylyx Pharmaceuticals, Inc. 57 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Amylyx Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMLX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $57 over the next 12 months.
Amylyx Pharmaceuticals, Inc. returned +144.6% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for diseases with significant unmet medical needs.
The most recent item we track (Seeking Alpha, 16 Sept 2026): "Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript". Amylyx Pharmaceuticals presented at the Morgan Stanley 24th Annual Global Healthcare Conference. A transcript of the presentation was made available on Seeking Alpha.
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for diseases with significant unmet medical needs. The company’s current pipeline centers on endocrine and neurodegenerative disorders, with avexitide as its lead investigational program. Avexitide is being studied as a first-in-class GLP-1 receptor antagonist for conditions linked to excessive insulin activity, including post-bariatric hypoglycemia and congenital hyperinsulinism. Amylyx also advances additional investigational therapies across other rare and serious diseases, reflecting a research portfolio built around well-defined biological targets and measurable clinical outcomes. Headquartered in Cambridge, Massachusetts, Amylyx Pharmaceuticals plays a role in the biotechnology market as a developer of targeted treatments for patients facing limited therapeutic options.
CEO Mr. Joshua B. Cohen · 136 employees · United States · https://amylyx.com
